3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
Selective glycogen synthase kinase 3 (GSK3) inhibition over cyclin dependent kinases such as cyclin dependent kinase 2 (CDK2) and cyclin dependent kinase 4 (CDK4) is an important requirement for improved therapeutic profile of GSK3 inhibitors. The concepts of selectivity and additivity fields have been employed in developing selective CoMFA models for these related kinases. Initially, sets of three individual CoMFA models were developed, using 36 compounds of bisarylmaleimide series to correlate with the GSK3, CDK2 and CDK4 inhibitory potencies. These models showed a satisfactory statistical significance: CoMFA-GSK3 (r(2)(con), r(2)(cv): 0.931, 0.519), CoMFA-CDK2 (0.937, 0.563), and CoMFA-CDK4 (0.892, 0.725). Three different selective CoMFA models were then developed using differences in pIC(50) values. These three models showed a superior statistical significance: (i) CoMFA-Selective1 (r(2)(con), r(2)(cv): 0.969, 0.768), (ii) CoMFA-Selective 2 (0.974, 0.835) and (iii) CoMFA-Selective3 (0.963, 0.776). The selective models were found to outperform the individual models in terms of the quality of correlation and were found to be more informative in pinpointing the structural basis for the observed quantitative differences of kinase inhibition. An in-depth comparative investigation was carried out between the individual and selective models to gain an insight into the selectivity criterion. To further validate this approach, a set of new compounds were designed which show selectivity and were docked into the active site of GSK3, using FlexX based incremental construction algorithm.
Dessalew
Nigus
N
Department of Pharmaceutical Chemistry, School of Pharmacy, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia. dnigus@phar.aau.edu.et
Bharatam
Prasad V
PV
D001185:Artificial Intelligence; D051357:Cyclin-Dependent Kinase 2 / Q000037:antagonists & inhibitors*; D051358:Cyclin-Dependent Kinase 4 / Q000037:antagonists & inhibitors*; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors*; D020128:Inhibitory Concentration 50; D008301:Maleimides / Q000737:chemistry* / Q000494:pharmacology*; D008958:Models, Molecular; D015394:Molecular Structure; D011485:Protein Binding; D021281:Quantitative Structure-Activity Relationship; D012984:Software; D013379:Substrate Specificity
D008301:Maleimides; D051357:Cyclin-Dependent Kinase 2; D051358:Cyclin-Dependent Kinase 4; D038362:Glycogen Synthase Kinase 3